Letter to the Editor | Published:

Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study

Leukemia volume 29, pages 16021604 (2015) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011; 152: 295–306.

  2. 2.

    , , , , , et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115: 4393–4402.

  3. 3.

    , , , , , et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther 2013; 12: 2031–2042.

  4. 4.

    , , , , , et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101–1110.

  5. 5.

    , , , , , et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446–5456.

  6. 6.

    , , , . Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 1995; 43: 130–137.

  7. 7.

    , . Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.

  8. 8.

    , , , , , et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164–1174.

  9. 9.

    , , , , , et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975–980.

  10. 10.

    , , , , , et al. Ofatumumab+chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911). Blood 2013; 122: 528.

  11. 11.

    , , , , , et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014; 15: 1090–1099.

  12. 12.

    , , , , , et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213–223.

  13. 13.

    , , , , , et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997–1007.

  14. 14.

    , , , , , et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014; 15: 48–58.

Download references

Author information

Affiliations

  1. German CLL Study Group (GCLLSG), Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

    • V Goede
    • , K Fischer
    • , A Engelke
    •  & M Hallek
  2. Oncology Practice, Würzburg, Germany

    • R Schlag
  3. Department of Hematology, Centre Henri Becquerel, Rouen, France

    • S Lepretre
  4. Department of Hematology, Hospital Virgen de la Salud, Toledo, Spain

    • L F C Montero
  5. Department of Hematology and Oncology, Ospedale Niguarda Ca’ Granda, Milan, Italy

    • M Montillo
  6. Department of Hematology, University Hospital of Wales, Cardiff, UK

    • C Fegan
  7. F. Hoffmann-La Roche Ltd, Basel, Switzerland

    • E Asikanius
    •  & G Fingerle-Rowson
  8. F. Hoffmann-La Roche Ltd, Welwyn, UK

    • K Humphrey
  9. Cluster of Excellence ‘Cellular Stress Responses in Aging Associated Diseases’ (CECAD), University of Cologne, Cologne, Germany

    • M Hallek

Authors

  1. Search for V Goede in:

  2. Search for K Fischer in:

  3. Search for A Engelke in:

  4. Search for R Schlag in:

  5. Search for S Lepretre in:

  6. Search for L F C Montero in:

  7. Search for M Montillo in:

  8. Search for C Fegan in:

  9. Search for E Asikanius in:

  10. Search for K Humphrey in:

  11. Search for G Fingerle-Rowson in:

  12. Search for M Hallek in:

Competing interests

VG, MM, CF and MH received honoraria from Roche. VG, KF and MH received research funding from Roche. AE received travel grants from Roche. VG, SL, MM, CF and MH declared consultancy or board membership for Roche. EA, KH and GF are paid employees and stockholders of Roche. The other authors declare no conflict of interest.

Corresponding author

Correspondence to V Goede.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/leu.2015.14

Further reading